Vasa previa: Perinatal outcomes in singleton and multiple pregnancies

Liu, Na; Hu, Qing; Liao, Huimin; Wang, Xiaodong; Yu, Haiyan

doi:10.5582/bst.2021.01052

Cited by 10 publications

(27 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Age was found to be related to the pregnancy rate (OR = 0.91, 95% CI = 0.88-0.94, P < 0.001) and pregnancy outcome (OR = 0.92, 95% CI = 0.86-0.98, P = 0.01), which was consistent with the results of previous studies (18,26). Older women may have an increased risk of impaired oocyte quality and chromosomal abnormalities and decreased endometrial receptivity (27)(28)(29). In addition, BMI also had an impact on the pregnancy rate (OR = 0.95, 95% CI = 0.90, 0.997, P = 0.04).…”

Section: Discussionsupporting

confidence: 89%

Association of MTHFR 677C>T polymorphism with pregnancy outcomes in IVF/ICSI-ET recipients with adequate synthetic folic acid supplementation

Zhang

et al. 2022

BST

View full text Add to dashboard Cite

Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphism rs1801133 (677C>T) will decrease the utilization of folate. Folate deficiency and its resulting homocysteine (HCY) accumulation can impair female fertility. Folic acid (FA) supplementation is necessary in pregnant women who are undergoing in-vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) -embryo transfer (ET), and especially in women with MTHFR rs1801133 C-to-T mutations. At present, affordable and accessible synthetic FA is mainly used. However, some studies have suggested that 5-methylenetetrahydrofolate (5-MTHF), a type of active FA, may be more suitable for women with the MTHFR 677C>T polymorphism, since it is safer and more effective. This retrospective study aimed to evaluate whether the MTHFR rs1801133 gene polymorphism is related to the pregnancy outcomes of IVF/ICSI-ET recipients after sufficient supplementation with FA instead of 5-MTHF. Data on 692 women undergoing IVF/ICSI-ET and taking adequate FA were collected. Participant characteristics were compared using the Kruskal-Wallis test and Pearson chi-square test. Logistic regressions were used to calculate the odds ratio (OR) and 95% confidence interval (95% CI), after adjusting for age, BMI, method of fertilization, method of embryo transfer and number of embryos transferred. An additive model (T/T vs.

show abstract

Section: Discussionsupporting

confidence: 89%

Association of MTHFR 677C>T polymorphism with pregnancy outcomes in IVF/ICSI-ET recipients with adequate synthetic folic acid supplementation

Zhang

et al. 2022

BST

View full text Add to dashboard Cite

show abstract

“…Figure 1 shows the selection scheme used in this study. First, 1364 studies were identified, and 20 studies met the study criteria for descriptive analysis [ 14 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 ]. Two studies reported by Suzuki et al [ 36 , 37 ] used overlapped data (due to overlapping study periods); however, the outcome of interest was different in these studies.…”

Section: Resultsmentioning

confidence: 99%

“…Regarding the study type ( n = 20), all studies were retrospective in nature, 14 were original articles, 4 were case series, and 2 were case reports. Of these ( n = 20), the published years were between 1998 and 2022, and all studies were retrospective [ 14 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 ]. No prospective studies or randomized controlled trials have been reported.…”

Section: Resultsmentioning

confidence: 99%

“…Among the eligible studies ( n = 20), approximately one-third were reported from Europe ( n = 6, 30.0%) [ 38 , 41 , 44 , 45 , 46 , 51 ] followed by Japan ( n = 5, 25.0%) [ 36 , 37 , 39 , 47 , 48 ], the United States ( n = 5, 25.0%) [ 14 , 35 , 43 , 49 , 52 ], and others ( n = 4, 20.0%) [ 34 , 40 , 42 , 50 ].…”

Section: Resultsmentioning

confidence: 99%

“…The risk of bias assessment for the included comparator studies is presented in Supplemental Table S2 . Among the studies ( n = 6), a possible moderate publication bias in three studies [ 40 , 42 , 43 ] and severe publication bias in the other three studies [ 39 , 41 , 44 ] were observed.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

The Characteristics and Obstetric Outcomes of Type II Vasa Previa: Systematic Review and Meta-Analysis

et al. 2022

View full text Add to dashboard Cite

Vasa previa is a rare fetal life-threatening obstetric disease classified into types I and II. This study aimed to examine the characteristics and obstetric outcomes of type II vasa previa. A systematic review was performed, and 20 studies (1998–2022) were identified. The results from six studies showed that type II vasa previa accounted for 21.3% of vasa previa cases. The characteristics and obstetric outcomes (rate of assisted reproductive technology (ART), antenatal diagnosis, emergent cesarean delivery, maternal transfusion, gestational age at delivery, and neonatal mortality) were compared between type I and II vasa previa, and all outcomes of interest were similar. The association between ART and abnormal placenta (bilobed placenta or succenturiate lobe) was examined in three studies, and the results were as follows: (i) increased rate of succenturiate lobes (ART versus non-ART pregnancy; OR (odds ratio) 6.97, 95% confidence interval (CI) 2.45–19.78); (ii) similar rate of abnormal placenta (cleavage-stage versus blastocyst embryo transfer); (iii) increased rate of abnormal placenta (frozen versus fresh embryo transfer; OR 2.97, 95%CI 1.10–7.96). Although the outcomes of type II vasa previa appear to be similar to those of type I vasa previa, the current evidence is insufficient for a robust conclusion.

show abstract

Timing of birth and adverse pregnancy outcomes in cases of prenatally diagnosed vasa previa: a systematic review and meta-analysis

Mitchell

Ngo

Maurel

et al. 2022

American Journal of Obstetrics and Gynecology

View full text Add to dashboard Cite

Vasa previa: Perinatal outcomes in singleton and multiple pregnancies

Cited by 10 publications

References 28 publications

Association of MTHFR 677C>T polymorphism with pregnancy outcomes in IVF/ICSI-ET recipients with adequate synthetic folic acid supplementation

Association of MTHFR 677C>T polymorphism with pregnancy outcomes in IVF/ICSI-ET recipients with adequate synthetic folic acid supplementation

The Characteristics and Obstetric Outcomes of Type II Vasa Previa: Systematic Review and Meta-Analysis

Timing of birth and adverse pregnancy outcomes in cases of prenatally diagnosed vasa previa: a systematic review and meta-analysis

Contact Info

Product

Resources

About